Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Activated partial thromboplastin time, Amaurosis fugax, Blood pressure measurement, Fatigue, Feeling hot
Clinical narrative: blurry vision (second dose)/blurry vision still comes and goes during the day; headache; sight went black; little pain in left arm; headache began of pain 6/10; a little body ache; a little more tired than usual; a little warm; This spontaneous case was reported by a consumer and describes the occurrence of VISION BLURRED (blurry vision (second dose)/blurry vision still comes and goes during the day) and AMAUROSIS FUGAX (sight went black) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011M20A and 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Anxiety (Improved in last 30 days.), Depression (Improved in last 30 days.) on 03-Aug-2017, Long COVID (Improved in last 30 days.) on 27-Nov-2020, GERD on 16-Oct-2018 and Iron deficiency anemia on 16-Oct-2018. Concomitant products included DESVENLAFAXINE SUCCINATE MONOHYDRATE (PRISTIQ) for Anxiety depression.   On 26-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-May-2021 at 11:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-May-2021, the patient experienced FEELING HOT (a little warm). 24-May-2021, the patient experienced MYALGIA (a little body ache) and FATIGUE (a little more tired than usual). On 25-May-2021, the patient experienced VISION BLURRED (blurry vision (second dose)/blurry vision still comes and goes during the day) (seriousness criterion hospitalization), AMAUROSIS FUGAX (sight went black) (seriousness criterion medically significant), PAIN IN EXTREMITY (little pain in left arm) and HEADACHE (headache began of pain 6/10). On 01-Jun-2021, the patient experienced HEADACHE (headache). The patient was hospitalized from 26-May-2021 to 27-May-2021 due to VISION BLURRED. The patient was treated with ACETAMINOPHEN at an unspecified dose and frequency and ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) at an unspecified dose and frequency. On 26-May-2021, VISION BLURRED (blurry vision (second dose)/blurry vision still comes and goes during the day) and AMAUROSIS FUGAX (sight went black) had resolved. At the time of the report, FEELING HOT (a little warm), PAIN IN EXTREMITY (little pain in left arm), MYALGIA (a little body ache), FATIGUE (a little more tired than usual) and HEADACHE (headache) outcome was unknown and HEADACHE (headache began of pain 6/10) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-May-2021, Activated partial thromboplastin time: 30.8 (Inconclusive) 30.8. In 2021, Blood pressure measurement: 110/59 (High) high. In 2021, Full blood count: abnormal (abnormal) abnormal.         Company Comment: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.   This case was linked to MOD-2021-187602 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Follow-up information received on 14 jun 2021 In patient tab patient demographic details, Medical history and lab data updated. In product tab treatment information updated. In event tab events updated On 18-Jun-2021: follow-up received on 18-Jun-2021 contains no new information; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.